ARTICLES BY MATTHEW PILLAR
The Compounded Risk Of Early-Stage Biopharma Licensing Deals
For emerging biopharma firms, licensing options can equal a boon to the business when cash runways are short and financing options run thin. But, there’s a catch. Most licensed candidates fail. And, according to a new paper, rushed licensing deals on the heels of phase 3 clinical failures only compound the disappointment.
Mechanistic Action: Genesis Of A Biologics Pipeline?
Cue Biopharma President & CSO Anish Suri, Ph.D. tells us why a partnership with The University Of Oxford to visualize the mechanistic action of molecules at the immunological synapse could provide insights that guide future drug discovery and development strategy.
Precision Medicine In Practice
Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.
Securing Biotech Funding When Economies Get Wild
There’s disruption on the startup biotech money trail. Navigating it requires a pliable strategy. Here, multi-time founder and investor Bert Liang shares insight on raising funds during volatile times.
A New Cost Paradigm For CAR Cell Therapies?
Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.
Is Biopharma’s Response To Coronavirus Off The Mark?
As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.